These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 12677894)

  • 1. [Amplification and overexpression of HER-2/neu in parotid gland salivary duct carcinoma. Immunohistochemical study and fluorescence in situ hybridization].
    Skálová A; Stárek I; Vanĕcek T; Kucerová V; Plank L; Szépe P
    Cesk Patol; 2002; 38 Suppl 1():27-34. PubMed ID: 12677894
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Expression of HER-2/neu gene and protein in salivary duct carcinomas of parotid gland as revealed by fluorescence in-situ hybridization and immunohistochemistry.
    Skálová A; Stárek I; Vanecek T; Kucerová V; Plank L; Szépe P; Di Palma S; Leivo I
    Histopathology; 2003 Apr; 42(4):348-56. PubMed ID: 12653946
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Amplification and overexpression of HER2/neu gene and HER2/neu protein in salivary duct carcinoma of the parotid gland.
    Cornolti G; Ungari M; Morassi ML; Facchetti F; Rossi E; Lombardi D; Nicolai P
    Arch Otolaryngol Head Neck Surg; 2007 Oct; 133(10):1031-6. PubMed ID: 17938328
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Her-2/neu gene amplification and protein expression in primary male breast cancer.
    Rudlowski C; Friedrichs N; Faridi A; Füzesi L; Moll R; Bastert G; Rath W; Büttner R
    Breast Cancer Res Treat; 2004 Apr; 84(3):215-23. PubMed ID: 15026619
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Amplification and overexpression of HER-2/neu in carcinomas of the salivary gland: correlation with poor prognosis.
    Press MF; Pike MC; Hung G; Zhou JY; Ma Y; George J; Dietz-Band J; James W; Slamon DJ; Batsakis JG
    Cancer Res; 1994 Nov; 54(21):5675-82. PubMed ID: 7522962
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Assessment of HER-2/neu overexpression and/or gene amplification in breast carcinomas: should in situ hybridization be the method of choice?
    Sauer T; Wiedswang G; Boudjema G; Christensen H; Karesen R
    APMIS; 2003 Mar; 111(3):444-50. PubMed ID: 12752225
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Determination of Her-2/Neu status in breast carcinoma: comparative analysis of immunohistochemistry and fluorescent in situ hybridization.
    Jimenez RE; Wallis T; Tabasczka P; Visscher DW
    Mod Pathol; 2000 Jan; 13(1):37-45. PubMed ID: 10658908
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Her-2/neu expression in salivary duct carcinoma: an immunohistochemical and chromogenic in situ hybridization study.
    Johnson CJ; Barry MB; Vasef MA; Deyoung BR
    Appl Immunohistochem Mol Morphol; 2008 Jan; 16(1):54-8. PubMed ID: 18091319
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Quantitation of HER-2/neu and c-myc gene amplification in breast carcinoma using fluorescence in situ hybridization.
    Persons DL; Borelli KA; Hsu PH
    Mod Pathol; 1997 Jul; 10(7):720-7. PubMed ID: 9237184
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Amplification of c-erbB2 oncogene: a major prognostic indicator in uterine serous papillary carcinoma.
    Santin AD; Bellone S; Van Stedum S; Bushen W; Palmieri M; Siegel ER; De Las Casas LE; Roman JJ; Burnett A; Pecorelli S
    Cancer; 2005 Oct; 104(7):1391-7. PubMed ID: 16116605
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Characterization of the HER-2/neu oncogene by immunohistochemical and fluorescence in situ hybridization analysis in oral and oropharyngeal squamous cell carcinoma.
    Khan AJ; King BL; Smith BD; Smith GL; DiGiovanna MP; Carter D; Haffty BG
    Clin Cancer Res; 2002 Feb; 8(2):540-8. PubMed ID: 11839675
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Lack of prognostic implications of HER-2/neu abnormalities in 345 stage I non-small cell carcinomas (NSCLC) and 207 stage I-III neuroendocrine tumours (NET) of the lung.
    Pelosi G; Del Curto B; Dell'Orto P; Pasini F; Veronesi G; Spaggiari L; Maisonneuve P; Iannucci A; Terzi A; Lonardoni A; Viale G
    Int J Cancer; 2005 Jan; 113(1):101-8. PubMed ID: 15386424
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Strong correlation between results of fluorescent in situ hybridization and immunohistochemistry for the assessment of the ERBB2 (HER-2/neu) gene status in breast carcinoma.
    Couturier J; Vincent-Salomon A; Nicolas A; Beuzeboc P; Mouret E; Zafrani B; Sastre-Garau X
    Mod Pathol; 2000 Nov; 13(11):1238-43. PubMed ID: 11106082
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Expression of HER-2/neu gene and protein in salivary duct carcinomas of parotid gland as revealed by fluorescence in-situ hybridization and immunohistochemistry.
    Dagrada GP; Negri T; Tamborini E; Pierotti MA; Pilotti S
    Histopathology; 2004 Mar; 44(3):301-2. PubMed ID: 14987238
    [No Abstract]   [Full Text] [Related]  

  • 15. An analysis of PLAG1 and HMGA2 rearrangements in salivary duct carcinoma and examination of the role of precursor lesions.
    Bahrami A; Perez-Ordonez B; Dalton JD; Weinreb I
    Histopathology; 2013 Aug; 63(2):250-62. PubMed ID: 23738717
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Amplification of Her-2/neu gene in Her-2/neu-overexpressing and -nonexpressing breast carcinomas and their synchronous benign, premalignant, and metastatic lesions detected by FISH in archival material.
    Xu R; Perle MA; Inghirami G; Chan W; Delgado Y; Feiner H
    Mod Pathol; 2002 Feb; 15(2):116-24. PubMed ID: 11850540
    [TBL] [Abstract][Full Text] [Related]  

  • 17. HER-2 gene amplification by fluorescence in situ hybridization (FISH) compared with immunohistochemistry (IHC) in breast cancer: a study of 528 equivocal cases.
    Zhang H; Ren G; Wang X; Zhao J; Yao H; Bai Y; Bo W
    Breast Cancer Res Treat; 2012 Jul; 134(2):743-9. PubMed ID: 22678158
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Potential for HER-2/neu molecular targeted therapy for invasive bladder carcinoma: comparative study of immunohistochemistry and fluorescent in situ hybridization.
    Matsubara H; Yamada Y; Naruse K; Nakamura K; Aoki S; Taki T; Tobiume M; Zennami K; Katsuda R; Honda N
    Oncol Rep; 2008 Jan; 19(1):57-63. PubMed ID: 18097576
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Assessment of HER2/Neu status by fluorescence in situ hybridization in immunohistochemistry-equivocal cases of invasive ductal carcinoma and aberrant signal patterns: a study at a tertiary cancer center.
    Murthy SS; Sandhya DG; Ahmed F; Goud KI; Dayal M; Suseela K; Rajappa SJ
    Indian J Pathol Microbiol; 2011; 54(3):532-8. PubMed ID: 21934215
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Non-invasive (intracapsular) carcinoma ex pleomorphic adenoma: recognition of focal carcinoma by HER-2/neu and MIB1 immunohistochemistry.
    Di Palma S; Skálová A; Vanìèek T; Simpson RH; Stárek I; Leivo I
    Histopathology; 2005 Feb; 46(2):144-52. PubMed ID: 15693886
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.